14.3 C
New York
Tuesday, March 21, 2023

Insights Into BioCryst Pharmaceuticals Inc. (BCRX) Exposure By Institutions

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for BioCryst Pharmaceuticals Inc. (BCRX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $8.86. The BioCryst Pharmaceuticals Inc. has recorded 348,888 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

BioCryst Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $8.86 and fluctuated between $8.90 as its day high and $8.62 as its day low. The current market capitalization of BioCryst Pharmaceuticals Inc. is $1.73B. A total of 2.74 million shares were traded on the day, compared to an average of 2.99M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, BCRX has seen 10 BUY and 8 SELL insider trades, representing the acquisition of 441,400 and the disposition of 143,645 shares. Over the last 12 months, there were 40 BUYs and 17 SELLs from insiders. Insiders purchased 1,153,560 shares during that period but sold 675,072.

In the most recent transaction, Stonehouse Jon P sold 100,000 shares of BCRX for 10.38 per share on Feb 01. After the transaction, the President & CEO now owns 1,008,739 company shares. In a previous transaction on Dec 15, Stonehouse Jon P sold 14,100 shares at 10.90 per share. BCRX shares that President & CEO owns now total 887,730.

Among the insiders who sold shares, Gayer Charles K disposed of 6,100 shares on Dec 15 at a per-share price of $10.90. This resulted in the Chief Commercial Officer holding 211,610 shares of BCRX after the transaction. In another insider transaction, Doyle Anthony sold 5,700 shares at $10.90 per share on Dec 15. Company shares held by the Chief Financial Officer now total 163,966.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for BCRX in the last 3 months, the mean price target is $15.45 with high estimates of $30.00 and low estimates of $8.00. In terms of 52-week highs and lows, BCRX has a high of $18.60 and a low of $7.61.

As of this writing, BCRX has an earnings estimate of -$0.17 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of $0.16 per share and a lower estimate of -$0.45. The company reported an EPS of -$0.32 in the last quarter, which was 5.90% higher than expectations of -$0.34.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 12 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCRX is Hold with a score of 4.08. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 5 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles